Scant Details, Comment Period for VBP Proposal Draw Concern

A new proposed rule (85 Fed. Reg. 37286, June 19, 2020), which CMS touted as a way to tweak Medicaid’s best-price provision to encourage more value-based purchasing (VBP) for expensive drugs, has drawn considerable criticism from stakeholders across the health care system. Experts say the rule is much more complex than it was initially made to seem, and the 30-day comment period is unusually short for such a substantial change.

“Generally, stakeholders across the board have voiced concerns with the short comment period,” Lindsay Bealor Greenleaf tells AIS Health. Greenleaf is vice president for policy at ADVI Health LLC, a health care consultancy. “There are a lot of complex proposals included in this rule that take time to unpack, to really analyze.”

© 2021 MMIT

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/Drug_Benefits_Life_Sciences.jpg
November 23

Will ‘Build Back Better’ Spell Disaster for Pharma Innovation?

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured-Image-health-plan-weekly-Wall-Street-Isnt-Sweating-Cignas-Third-Quarter-MLR-Miss.jpg
November 23

Big Three PBMs’ 3Q Results Make Up for Insurer Disappointments

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2021/11/WordPress-Featured_AdobeStock_442155384.jpg
November 23

SCAN Health Opts to Invest in Medication Adherence Tool

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today